Novocure Strategy and Business Model

Executive Overview

Novocure is a commercial-stage oncology company built around Tumor Treating Fields, or TTFields, a non-invasive cancer therapy that uses low-intensity, intermediate-frequency electric fields to disrupt tumor cell division. Founded in 2000 by Professor Yoram Palti and headquartered in Root, Switzerland, with a substantial research footprint in Israel and a Nasdaq listing in the United States, Novocure sits between medtech and oncology therapeutics. Its current commercial business is centered on Optune Gio for glioblastoma and Optune Lua for malignant pleural mesothelioma, delivered through a portable field generator, transducer arrays, and ongoing patient-support services. In FY2024, Novocure reported revenue of #N/A. The company sells directly in the United States, much of Europe, and Japan, and uses partnerships in selected markets, including Greater China. Strategically, Novocure is not trying to become a broad hospital-device vendor. It is trying to establish TTFields as a repeatable oncology platform across multiple solid tumors. That makes clinical evidence generation, regulatory execution, reimbursement, physician adoption, and patient adherence more important to value creation than simple device placements.

Novocure at a Glance

Logo
Common name	Novocure
Full legal name	Novocure Ltd.
Headquarters	Root, Switzerland (principal executive office); registered office in Saint Helier, Jersey
Ownership	Public company; Nasdaq-listed; no controlling shareholder disclosed in public filings as of 2024
Ticker	NVCR
Exchange	NASDAQ
Market Cap	$1.65B
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 2000 by Professor Yoram Palti; U.S. approval in recurrent glioblastoma in 2011; U.S. approval in newly diagnosed glioblastoma in 2015; Nasdaq IPO in 2015; U.S. approval for malignant pleural mesothelioma in 2019
Industry or industries	Oncology, medical devices, cancer therapeutics
Key products or services	Optune Gio, Optune Lua, TTFields therapy, transducer arrays, patient-support services, reimbursement support
Geographic footprint	Direct commercial presence in the United States, Europe, and Japan; partnered presence in selected markets including Greater China; global clinical-trial network
Business segments as officially reported	One reportable segment as of FY2024
Company website	https://www.novocure.com

1. What Is the Strategy of Novocure?

Novocure’s public communications through 2024 consistently frame the company as a platform-oncology business rather than a single-indication device company. In Playing to Win terms, the strategy is to prove TTFields in carefully chosen tumor types, secure reimbursement, and build the operating system needed to support long-duration therapy at scale.

1a. What is the winning aspiration of Novocure?

Novocure’s winning aspiration is to make TTFields a standard component of care in selected solid tumors with high unmet need. In practical terms, winning means more than maintaining its glioblastoma franchise. It means showing survival benefit in additional indications, securing regulatory approvals, earning payer coverage, and building enough physician confidence that TTFields becomes part of routine treatment algorithms. As of 2024, management messaging emphasized extending survival in aggressive cancers and broadening the number of approved indications rather than promising a single headline revenue target.
1b. Where does Novocure play?

Novocure plays in adult oncology, specifically in tumor settings where a wearable, non-invasive electric-field therapy can be added to standard treatment. Commercially, that has meant glioblastoma and malignant pleural mesothelioma. Development priorities as of 2024 also included metastatic non-small cell lung cancer, pancreatic cancer, brain metastases from non-small cell lung cancer, ovarian cancer, and earlier-line use in newly diagnosed glioblastoma. Geographically, Novocure focuses on markets with sophisticated oncology infrastructure and reimbursement systems, especially the United States, Europe, and Japan, while using partners in certain markets such as Greater China.
1c. How does Novocure plan to win?

Novocure is not pursuing a cost-leadership model. It aims to win through differentiation: a distinct mechanism of action, add-on use with existing standards of care, portable at-home treatment, and a body of clinical evidence designed to support survival claims. The company also tries to reduce friction around a therapy that patients must wear for much of the day, which makes onboarding, support, and adherence services part of the competitive proposition. In effect, Novocure is selling a therapy platform plus an operating model, not just a device.
1d. What capabilities must Novocure have in place?

To execute this strategy, Novocure needs several capabilities that are harder than they look. It needs strong clinical-trial design and execution in oncology, deep regulatory expertise for a novel device-based therapy, computational and engineering capabilities to optimize electric-field delivery, reliable manufacturing and logistics for recurring consumables, payer and health-economics capabilities to support reimbursement, and specialized commercial teams that can educate oncologists while helping patients remain on therapy. Because treatment duration matters, patient-support capability is strategically important, not just operationally useful.
1e. What management systems does Novocure require?

Novocure requires management systems that link clinical evidence, quality compliance, commercial execution, and capital allocation. That includes medical-device quality systems, post-market surveillance, usage and adherence monitoring, reimbursement authorization workflows, launch-readiness planning for new indications, and portfolio governance across multiple expensive clinical programs. A practical read of the company suggests that milestone-based trial management and disciplined spending controls are especially important, because Novocure is funding a broad pipeline from a still-concentrated commercial base.

2. What Are the Current Strategic Initiatives of Novocure?

Based on company disclosures and investor materials through 2024, Novocure’s major strategic initiatives are relatively clear.

Protect and expand the core glioblastoma business. Glioblastoma remains the commercial foundation. That means growing active-patient counts, improving treatment initiation, increasing adherence and duration on therapy, and sustaining physician confidence in Optune Gio as part of standard management for eligible adult patients.
Convert positive lung-cancer data into a regulatory and commercial opportunity. After reporting positive phase 3 LUNAR data in metastatic non-small cell lung cancer in 2023, Novocure’s 2024 agenda included regulatory preparation, launch planning, and market-development work for what could become its largest new indication.
Advance late-stage pipeline programs. As of 2024, Novocure continued to invest in pivotal or late-stage studies including PANOVA-3 in locally advanced pancreatic cancer, TRIDENT in newly diagnosed glioblastoma, METIS in brain metastases from non-small cell lung cancer, and INNOVATE-3 in ovarian cancer. These programs are central because they test whether TTFields can scale beyond niche use.
Build payer and reimbursement support for broader use. For Novocure, reimbursement is not a back-office issue. It is one of the main gating factors to adoption, especially in new indications and outside the United States.
Improve product usability and operational readiness. The company continues to refine device form factor, arrays, and support processes. That matters because treatment burden can influence adherence, and adherence can influence both outcomes and commercial durability.
Manage spending while funding expansion. Novocure has to balance heavy clinical-investment requirements with a revenue base that remains concentrated in a limited number of approved indications. Portfolio prioritization and cost discipline therefore remain ongoing strategic themes.

3. What Is the Business Model of Novocure?

What customers actually buy

Customers do not primarily buy capital equipment in the traditional hospital-device sense. They buy a prescribed cancer therapy package: access to the TTFields device platform, recurring transducer arrays and accessories, treatment planning, training, and ongoing support. The patient wears the device at home, while the physician prescribes and oversees therapy and the payer ultimately funds most of the economics.

Recurring versus one-time revenue

Novocure’s model appears mostly recurring and repeat-driven. Each active patient generally requires ongoing therapy over time, along with regular replacement arrays and support. That creates a monthly revenue stream tied more to treatment duration and active-patient counts than to one-off equipment sales. This is one reason the installed base of active patients matters so much.

How pricing power works

Pricing power exists, but it is constrained by reimbursement and evidence. Novocure’s therapy is differentiated and has few direct device analogues, which helps. But because oncology care is payer mediated, durable pricing depends on demonstrated clinical value, health-economic support, and coding and coverage decisions. In other words, the company cannot rely on brand alone; it must keep proving value.

Why the business mix matters

Business mix matters in two ways. First, current revenue appears heavily concentrated in glioblastoma, so indication concentration is still high. Second, geographic mix affects reimbursement pathways, pricing, and collections. A new indication such as metastatic non-small cell lung cancer could matter disproportionately because it would diversify the company away from a brain-tumor-heavy base and potentially expand the addressable population materially.

What drives margins and cash generation

Gross margin is influenced by the economics of device manufacturing, array production, logistics, service support, and payer mix. Operating margin is more heavily shaped by clinical-trial spending, specialty commercial infrastructure, and market-access investment. Cash generation benefits from an asset-lighter manufacturing approach than a traditional factory-heavy device business, but it is offset by significant research and development outlays and by working-capital demands tied to payer reimbursement cycles.

Revenue model

The revenue model is best understood as a recurring therapy model rather than a subscription in the software sense or a one-time hardware sale. Revenue scales with active patients, treatment duration, payer approvals, and the company’s ability to keep patients supplied and supported.

4. What Products and/or Services Does Novocure Sell?

Novocure’s commercial offering is concentrated but strategically distinctive.

Optune Gio. Novocure’s core commercial product for adult patients with certain glioblastoma indications. It is a portable TTFields system used with transducer arrays placed on the scalp.
Optune Lua. The company’s TTFields system for adult patients with unresectable, locally advanced or metastatic malignant pleural mesothelioma, used in combination with pemetrexed and platinum-based chemotherapy.
Transducer arrays, batteries, accessories, and replacement supplies. These recurring consumables are essential to ongoing therapy and are economically important because treatment is continuous rather than episodic.
Patient-support services. Novocure provides onboarding, training, array-change guidance, reimbursement support, and ongoing assistance to help patients stay on therapy.
Clinical and reimbursement support infrastructure. This is not sold as a separate software product, but it is part of the value proposition to physicians and patients.

As of 2024, glioblastoma appears to drive the large majority of revenue. Mesothelioma is commercially meaningful but smaller. The newer growth opportunity lies less in new brands than in expanding the same TTFields platform into additional tumor types.

5. What Are the Key Competitors or Peers of Novocure?

Novocure has few pure-play direct competitors because TTFields is an unusual modality. A more useful competitive map includes therapeutic alternatives in the cancers it serves and a handful of oncology-device peers that face similar evidence and specialist-selling dynamics.

Merck & Co. A major competitive alternative in thoracic oncology through immunotherapy regimens such as Keytruda. It matters especially in non-small cell lung cancer and mesothelioma treatment pathways.
AstraZeneca. A leading player in lung cancer with targeted therapies and immuno-oncology products. It competes for physician attention and treatment sequencing in lung cancer settings where Novocure aims to expand.
Bristol Myers Squibb. Another major oncology competitor in thoracic cancers through checkpoint-inhibitor regimens and combination therapy approaches.
Roche / Genentech. Important both because of historical relevance in recurrent glioblastoma through bevacizumab and because of its broad presence in hospital oncology.
Siemens Healthineers / Varian. A radiation-oncology equipment peer whose systems are used in many of the same cancer centers. Radiation is not a direct substitute for TTFields in all cases, but it is part of the broader local-therapy competitive set.
Elekta. Another significant radiation-oncology systems provider serving many of the same institutions and decision makers.
Accuray. A precision-radiation peer with systems such as CyberKnife and TomoTherapy that compete in certain brain and thoracic treatment contexts.
Insightec. Not a direct indication-for-indication competitor, but a relevant peer as a company built around a non-invasive, energy-based treatment platform with specialist adoption and evidence-generation demands.

The broader point is that Novocure often competes less against another device maker and more against entrenched drug and radiation pathways. That raises the bar for evidence and reimbursement but also means success can create a category of its own.

6. What Is the Marketing Strategy of Novocure?

Novocure’s marketing strategy is clinical and evidence led. This is not a mass-market medtech brand that can be built mainly through consumer advertising. Adoption depends on specialist physicians, tumor boards, academic centers, community-oncology opinion leaders, and payers.

In practice, that means Novocure leans heavily on:

Scientific marketing. Publications, conference presentations, clinical-data dissemination, and physician education are central.
Field-based specialist engagement. Commercial and clinical teams support neuro-oncologists, medical oncologists, radiation oncologists, and related care teams.
Patient and caregiver education. Because the therapy requires daily wear and lifestyle adjustment, patient understanding and confidence are unusually important to conversion and persistence.
Market-access communication. Payer-facing evidence, reimbursement support, and treatment-pathway education are part of commercialization, not separate from it.

Marketing is therefore a supporting capability, but an important one. It works best when integrated with medical affairs, reimbursement, and patient support rather than treated as a standalone brand campaign.

7. What Are the Key Customer Segments of Novocure?

Novocure effectively serves three linked customer groups at once: prescribers, patients, and payers.

Specialist physicians and cancer centers. Neuro-oncologists, neurosurgeons, medical oncologists, radiation oncologists, and thoracic-oncology teams are the prescribers and gatekeepers to use.
Adult patients and caregivers. Patients are the daily users of the therapy, and caregiver support often matters because the device must be worn consistently and arrays must be changed regularly.
Payers and reimbursement authorities. Commercial insurers, public payers, and national health systems are economically critical because therapy cost and access depend on coverage.

By indication, Novocure’s current revenue base is still concentrated in glioblastoma, with mesothelioma as a smaller second commercial segment. That means the company is not yet broadly diversified by end market. Future launches in lung cancer, pancreatic cancer, and other tumors are strategically important partly because they would diversify the customer base by disease setting and physician specialty.

8. What Is the Sales Model of Novocure?

Novocure uses a specialty, prescription-driven sales model. It does not rely primarily on distributors moving inventory into hospitals. Instead, the company calls on prescribing physicians and cancer centers, helps navigate reimbursement, and then delivers therapy to patients with ongoing support.

The model typically works like this:

Novocure’s field teams educate physicians and treatment centers.
A physician prescribes TTFields therapy for an eligible patient.
Novocure supports benefits verification, authorization, and onboarding.
The device and supplies are delivered, and the patient is trained on use.
Recurring supplies and support continue over the treatment period.

In many core markets, Novocure commercializes directly. In selected geographies, it uses partnerships; Greater China has been a prominent example. This channel structure improves customer intimacy and data visibility, but it also makes scaling more operationally complex. Growth depends on field-force productivity, reimbursement conversion, and adherence support as much as on simple account penetration.

9. In What Geographies Does Novocure Operate?

Novocure operates globally, but its commercial footprint is concentrated in higher-income markets with advanced oncology infrastructure. As of 2024, the United States remained its largest market, with additional direct commercial activity across Europe and Japan. The company has also used partnership structures in selected markets, including Greater China.

Operationally, Novocure’s footprint includes:

Switzerland. Principal executive office and corporate leadership.
Israel. A substantial research, development, and engineering base linked to the company’s origins.
United States. Major commercial, market-access, clinical, and support infrastructure.
Europe and Japan. Regional commercial teams and market-access activity.
Global clinical-trial network. Multinational trial sites are important because the company is expanding indications through late-stage studies.

Novocure is geographically diversified enough to be more than a single-country company, but its economics are still concentrated in a limited set of reimbursed markets rather than broadly spread across the globe.

10. Who Are the Owners of Novocure?

Novocure is a publicly traded company on Nasdaq. As of the company’s 2024 proxy and annual-report disclosures, it did not report a controlling shareholder. Ownership appears primarily institutional and broadly dispersed, which is typical for a mid-cap public medtech company. Public-market filings around 2024 indicated that large diversified asset managers such as BlackRock and The Vanguard Group were among notable shareholders, but no single owner appeared to control strategy or voting outcomes outright.

11. How Is Novocure Organized?

As of FY2024, Novocure reported one reportable segment. That is consistent with how management appears to view the company: a single TTFields platform business rather than a portfolio of unrelated units.

Practically, however, Novocure is organized across several operating dimensions:

Commercial functions by geography and tumor area
Clinical development and medical affairs for pipeline studies and evidence generation
Research and engineering for device, array, and field-modeling development
Technical operations and supply chain for manufacturing, quality, and logistics
Corporate functions such as finance, regulatory, legal, and human resources

Legally, the company uses a multinational holding structure with subsidiaries across commercial and operating jurisdictions. From a management standpoint, though, the important fact is that Novocure still behaves like a focused platform company: one technology, a small number of commercial indications, and a pipeline intended to broaden that platform.

12. How Does Novocure Operate?

Novocure’s day-to-day operations are unusual because it combines medical-device logistics, oncology evidence generation, reimbursement navigation, and home-based therapy support.

Generate demand through clinical evidence and physician education. The company must maintain specialist awareness and support trial and real-world evidence.
Convert prescriptions into reimbursed starts. Once a physician prescribes therapy, Novocure works through authorization and coverage processes.
Set up the patient for home use. The patient receives the device, arrays, training, and practical guidance.
Supply recurring consumables. Arrays and accessories must be replenished reliably throughout treatment.
Support adherence and troubleshooting. Wear-time, skin management, and patient experience are operationally important because therapy is continuous.
Bill and collect. Reimbursement and collections are integral to performance.
Run late-stage clinical programs. At the same time, Novocure is operating pivotal studies intended to open new indications.

The main operational complexity is that commercial success depends on more than selling into a hospital. Novocure must sustain thousands of small but critical interactions over time: authorizations, shipments, training, follow-up, and support. Any breakdown can hurt patient experience, treatment continuity, or reimbursement.

13. What Are the Growth Opportunities for Novocure?

Novocure’s most plausible growth opportunities are visible and specific.

New indication approvals. The biggest opportunity is turning TTFields into a multi-indication oncology platform. Metastatic non-small cell lung cancer was the clearest near-term opportunity in 2024 because of positive LUNAR data.
Pancreatic cancer and other late-stage pipeline programs. Positive results in PANOVA-3, METIS, TRIDENT, or INNOVATE-3 would materially widen the addressable market.
Deeper glioblastoma penetration. Even without a new tumor-type approval, Novocure can still grow through better diagnosis-to-start conversion, longer duration, and broader physician adoption in eligible patients.
Geographic expansion and reimbursement wins. Coverage in additional countries or broader lines of therapy can unlock growth without requiring a new technology platform.
Combination-treatment use cases. TTFields is designed to be used alongside chemotherapy, radiation, or immunotherapy, which creates room for broader regimen inclusion if data support it.
Usability improvements. Better form factor, arrays, and support processes could improve adherence and therefore commercial productivity.

The main constraints are also clear: clinical-trial risk, regulatory uncertainty, reimbursement hurdles, dependence on physician behavior, and the practical burden of a wearable therapy. Novocure’s upside is large if the platform expands, but its concentration in one core technology means execution risk is also concentrated.

14. What Is the History of Novocure?

Novocure was founded in 2000 by Professor Yoram Palti, an Israeli physicist and physician, to commercialize the concept of using electric fields to interfere with cancer cell division. The company spent its early years developing the TTFields platform and generating clinical evidence around brain tumors.

A major milestone came in 2011, when the U.S. Food and Drug Administration approved Novocure’s therapy for recurrent glioblastoma. In 2015, Novocure achieved a much more consequential step when the therapy gained approval for newly diagnosed glioblastoma in combination with temozolomide after chemoradiation. The company also completed its Nasdaq initial public offering in 2015.

In 2018, Novocure entered a major collaboration with Zai Lab for Greater China, underscoring its willingness to use partners where local execution and market access required it. In 2019, the company received U.S. approval under a Humanitarian Device Exemption for malignant pleural mesothelioma, extending TTFields beyond brain tumors. By 2023 and 2024, Novocure had evolved from a glioblastoma-focused company into a broader platform-oncology business pursuing late-stage programs in lung cancer, pancreatic cancer, ovarian cancer, and brain metastases.

15. What Are the Key Suppliers to Novocure?

Suppliers matter strategically to Novocure because the company depends on reliable production and delivery of both device hardware and recurring consumables. In its public filings, Novocure has emphasized reliance on a limited number of third-party suppliers and contract manufacturers for certain key components.

The most important supplier categories appear to include:

Contract manufacturers for the device platform and related assemblies
Suppliers of transducer arrays and specialized materials used directly in therapy delivery
Electronics and component vendors for power systems, cables, and control hardware
Battery and accessory suppliers that affect portability and patient experience
Logistics and distribution partners that move therapy kits and recurring supplies to patients

Public disclosures have generally highlighted supplier concentration risk more than they have highlighted a branded supplier roster. Strategically, that matters because treatment interruptions can disrupt patient therapy, and new indication launches could sharply increase demand for arrays and support logistics.

16. What Are the Key Brands Owned by Novocure?

Branding matters at Novocure, but clinical evidence matters more. The main commercial brands are tied to indication-specific therapy offerings built on the same TTFields platform.

Optune Gio. The flagship commercial brand for glioblastoma. It represents the portable device platform and the treatment experience built around it.
Optune Lua. The mesothelioma-specific brand. The separate branding helps Novocure speak to thoracic-oncology use cases rather than only neuro-oncology.
TTFields. Not a patient-facing brand in the same way as Optune, but arguably the most important strategic brand asset. It is the scientific and platform identity that underpins the company’s expansion story.

Novocure is not a classic consumer-brand company. The strongest brand signal in its market is credible data, physician familiarity, and confidence that patients can stay on therapy.

17. How Does the Supply Chain of Novocure Function?

Novocure’s supply chain is built around continuous therapy rather than episodic procedures. That changes what matters operationally.

Sourcing. The company must secure specialized electronics, device components, arrays, accessories, and packaging materials.
Manufacturing. Novocure appears to use third-party manufacturing rather than operating a large owned-factory network, which reduces capital intensity but increases supplier-management importance.
Inventory and fulfillment. Because patients need ongoing arrays and accessories, the company must forecast usage, hold appropriate inventory, and replenish reliably.
Patient delivery. Supply-chain execution extends to the home. This is unusual for oncology and makes last-mile logistics strategically important.
Service and replacement. Devices must be maintained, replaced, or serviced when needed, without disrupting treatment.

Reliability matters more than sheer physical scale. A missed shipment or device issue can interrupt therapy for an individual patient, which directly affects both clinical experience and revenue continuity. As a result, Novocure’s supply chain is a strategic enabler of adherence.

18. What Is the Technology Strategy of Novocure?

Technology is the center of Novocure’s strategy, not just a support function. The company’s competitive position depends on whether it can keep advancing TTFields as a differentiated treatment platform.

Its technology strategy appears to include several layers:

Core field-delivery science. The company must generate therapeutic electric fields with the right characteristics for specific tumor settings.
Treatment planning and array configuration. Practical effectiveness depends on how well the system can target relevant anatomy and support correct array placement.
Device portability and usability. Better form factor, power management, and ease of use can lower patient friction and support adherence.
Data and monitoring. Connected-device information can help Novocure understand usage, support patients, and improve operations.
Intellectual property. Patents and know-how are important because the platform is novel and technically specific.

Technology serves both as the customer offering and as an internal enabler. For Novocure, engineering, software, clinical evidence, and device design are inseparable parts of the same moat.

19. What Is the R&D Strategy of Novocure?

R&D is one of the defining features of Novocure’s model. The company is using research and development primarily to extend one core platform into additional tumor types rather than to build a broad portfolio of unrelated products.

As of 2024, the R&D strategy centered on:

Large late-stage clinical trials. These included LUNAR in metastatic non-small cell lung cancer, PANOVA-3 in locally advanced pancreatic cancer, TRIDENT in newly diagnosed glioblastoma, METIS in brain metastases from non-small cell lung cancer, and INNOVATE-3 in ovarian cancer.
Combination-therapy research. TTFields is designed to work alongside chemotherapy, radiation, or immunotherapy, so combination evidence is strategically important.
Platform refinement. Novocure continues to invest in device and array improvements that can make therapy easier to use and potentially more effective.
Mechanism and translational work. Because TTFields is a distinctive modality, ongoing scientific work helps support physician confidence and future trial design.

The R&D challenge is straightforward: the company must spend enough to prove platform breadth, but those trials are long, expensive, and operationally demanding. If successful, however, they can transform Novocure from a niche commercial company into a broader oncology platform business.

20. What Is the Finance Strategy of Novocure?

Novocure’s finance strategy has generally looked like that of a growth-stage oncology platform company rather than a mature medical-device cash-distributor. Through FY2024, the company appeared focused on preserving liquidity, funding pivotal trials, supporting the core commercial franchise, and staging spend against regulatory and market-access milestones.

Several elements stand out:

Reinvestment over distribution. Capital has been directed primarily toward clinical development, market access, product support, and launch readiness rather than dividends or large shareholder-return programs.
Operating leverage depends on indication expansion. The company already has a commercial and support infrastructure, so new high-volume indications could improve fixed-cost absorption if launched successfully.
Working capital and collections matter. Because reimbursement cycles can be complex, cash conversion depends not only on revenue growth but also on payer collections and operational discipline.
Low capital intensity, high evidence intensity. Novocure is less factory-intensive than many hardware businesses, but much more trial-intensive than typical device companies.

At a strategic level, finance supports the broader corporate goal of buying enough time and capacity to turn TTFields from a concentrated glioblastoma business into a broader multi-indication platform.

21. How Companies Like Novocure Leverage Independent Consultants through Umbrex

Umbrex has built a global community of more than 8,000 independent management consultants in more than 50 countries, many of them alumni of McKinsey, Bain, BCG, and other top consulting firms. Companies like Novocure engage Umbrex when they need that level of strategic and operational talent but do not need a full consulting team with all the overhead. Umbrex has consultants across strategy, operations, organization, marketing, sales, finance, technology, ERP, and AI. For a company with Novocure’s mix of oncology evidence generation, specialty commercialization, reimbursement complexity, and platform scaling, representative projects include:

Designing a launch strategy and 24-month operating plan for a new indication such as metastatic non-small cell lung cancer.
Building a global market-access and reimbursement roadmap for lung, pancreatic, and other future tumor indications.
Redesigning the patient journey to improve therapy initiation speed, adherence, and duration on treatment.
Optimizing specialty field-force sizing, territory design, account targeting, and key-opinion-leader engagement across academic and community oncology centers.
Creating supply-chain resilience plans for arrays, devices, accessories, and home-delivery logistics ahead of a major indication expansion.
Developing portfolio-prioritization and capital-allocation scenarios across late-stage programs such as LUNAR, PANOVA-3, METIS, TRIDENT, and INNOVATE-3.
Improving clinical-operations performance through site-activation analytics, enrollment diagnostics, and study-governance redesign.
Assessing partner strategy and governance models for Greater China and other partner-led international markets.
Building health-economics value stories and payer materials to support reimbursement negotiations and appeals.
Designing data, analytics, and AI use cases for forecasting, patient-support operations, field-force productivity, and connected-device insights.